A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

Inclusion Criteria:

• Participants ≥18 years of age at screening visit

• Participants with documented and confirmed diagnosis of any of the below diseases:

• B-cell CLL according to International Workshop on CLL (iwCLL) criteria and RAIstaging of intermediate (1 and 2) or high (3 and 4)

• MM according to the International Myeloma Working Group criteria (IMWG), R-ISSstage II or, III; or

• Histologically confirmed diagnosis of B-Cell NHL, Stage III or above (IV,Progressive/refractory, or recurrent/relapsed stage) according to the LuganoClassification.

• Participants with HGG with IgG levels less than 5 g/L.

• Participants with documented history of at least one severe bacterial infection (bacterial or viral) or recurrent bacterial/viral infections (that is., ≥ 3infections) within 12 months before the screening visit. Severe bacterial/viralinfections ≥ Grade 3 (as defined by Common Terminology Criteria for Adverse Events [CTCAE] Grades).

Exclusion Criteria:

• Participants with documented history of hematopoietic stem cell transplant.

• Participants currently receiving immunoglobulin replacement therapy (IgRT) or havereceived IgG replacement treatment (i.e., prior immune globulin replacement therapy)within 6 months before the screening visit.

• Participants with active infections at time of screening visit. Specific supportiveanti-infective prophylactic defined in the CLL National Comprehensive Cancer Network (NCCN) or iwCLL guidelines and/or local/international guidelines for the CLL, anddefined in local/international guidelines for MM and NHL are allowed, or recommendedin the updated labelling of specific active target disease medicines used during theparticipation in the trial is also allowed.

• Participants with active second malignancies.

• Participants with known primary immunodeficiency (PI).

• Participants with a life expectancy less than 1.5 years.

• Participants with clinical evidence of any significant acute or chronic diseasethat, in the opinion of the investigator, may interfere with successful completionof the trial or place the subject at undue medical risk.

• Participants have had a known serious adverse reaction (AR) to immunoglobulin or anyanaphylactic reaction to blood or any blood-derived product.

• Participants have a history of blistering skin disease, bleeding disorder, diffuserash, recurrent skin infections, or other disorders where SC therapy would becontraindicated during the study based upon the Investigator's discretion.

• Participants have known Selective Immunoglobulin A (IgA) Deficiency (with or withoutantibodies to IgA) (Note: exclusion is for the specific diagnostic entity. It doesnot exclude other forms of humoral primary immunodeficiency which have decreased IgAin addition to decreased IgG requiring IgG replacement).

• Participants with severe known kidney disease [as defined by estimated glomerularfiltration rate [eGFR] less than (<) 30 milliliter (mL)/min/1.73 squaremeter (m2)] as determined by the Principal Investigator.

• Participants that have liver enzyme levels (alanine aminotransferase [ALT],aspartate aminotransferase [AST], gammaglutamyl transferase [GGT], or lactatedehydrogenase [LDH]) greater than 3 times the upper limit of normal (ULN) at theScreening Visit as defined by the testing laboratory.

• Participants have a history (either 1 episode within the year prior to the ScreeningVisit or 2 previous episodes over a lifetime) of or current diagnosis ofthromboembolism (example, myocardial infarction, cerebrovascular accident, ortransient ischemic attack) or deep venous thrombosis.

• Participants are currently receiving anti-coagulation therapy which would make SCadministration inadvisable (vitamin K antagonists, nonvitamin K antagonist oralanticoagulants [example, dabigatran etexilate targeting Factor IIa, rivaroxaban,edoxaban, and apixaban targeting Factor Xa], and parenteral anticoagulants [example,fondaparinux]).

• Participants currently have a known hyperviscosity syndrome or hypercoagulablestates.

• Participants have a known previous infection or clinical signs and symptomsconsistent with current hepatitis B virus or hepatitis C virus infection.

• Participants with non-controlled arterial hypertension (systolic blood pressure [SBP] greater than 140 millimeters of mercury (mmHg) and/or diastolic blood pressure [DBP] greater than 90 mmHg), and/or a heart rate (HR) greater than100 bpm.

• Participants with known substance or prescription drug abuse within 12 months beforethe Screening Visit.

• Participants have participated in another clinical trial within 30 days prior toscreening (observational studies without investigative treatments [non-interventional] are permitted).